Could a 3-Month pill course spare older breast cancer patients from radiation?

NCT ID NCT06507618

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This Phase III trial is for women aged 65 and older with early-stage, hormone-sensitive breast cancer. Half will take hormone-blocking pills for three months before surgery, while the other half will proceed directly to surgery as usual. The goal is to see if the pre-surgery pills help women feel more confident about skipping radiation therapy afterward. The study will track how well women tolerate the pills and whether they stick with the treatment plan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

endocrine therapy (tamoxifen, letrozole, anastrozole, or exemestane)

What this could lead to

If successful, this approach could help older women with early breast cancer avoid unnecessary radiation therapy by using a short course of hormone-blocking pills before surgery.

What could go wrong

This is a Phase III trial, but it focuses on decision-making and adherence, not on curing cancer. The results may not apply to younger women or those with more aggressive tumors. Side effects from endocrine therapy can include hot flashes, joint pain, and fatigue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm estrogen-receptor positive breast cancer female breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • INOVA Schar Cancer

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Phone: •••-•••-••••

  • Riverside Health System

    RECRUITING

    Newport News, Virginia, 23601, United States

  • University of Virginia

    RECRUITING

    Charlottesville, Virginia, 22903, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Virginia Community Health

    RECRUITING

    Culpeper, Virginia, 22701, United States

    Contact Email: •••••@•••••

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23298, United States

    Contact Email: •••••@•••••

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06511, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••